Strong evidence · Grade A
Small molecule · not a peptide
Orforglipron
Orforglipron (Foundayo)
Score
82 / 100
Type
Small molecule (non-peptide)
Route
Oral, once daily
Status
Phase 3 (filing-stage)
TL;DR
01
An oral, once-daily GLP-1 receptor agonist from Eli Lilly — importantly a small molecule, NOT a peptide — poised to be the first pill in the high-efficacy weight-loss class.
02
In its phase 3 obesity trial (ATTAIN-1, ~3,100 people), the top dose produced about 11% weight loss at 72 weeks versus ~2% on placebo.
03
In early type 2 diabetes (ACHIEVE-1) it lowered HbA1c by roughly 1.5 points and cut weight ~7.6%.
04
Its big advantage is that it's a pill, not an injection — but its weight-loss ceiling (~11%) is below injectable semaglutide (~15%) and tirzepatide (~20%).
05
Side effects are the familiar GLP-1 gastrointestinal effects; it is in late-stage development, not yet approved.
Wt loss (ATTAIN-1, 36 mg)
−11.2%
NEJM 2025 · 72 wk
≥15% weight loss
36%
36 mg arm
HbA1c (ACHIEVE-1)
−1.48 pp
early T2D · 40 wk
vs injectables
Lower ceiling
<sema ~15% / tirze ~20%
Advantage
Oral pill
no injection
Part 01 · How it works
Mechanism.
Orforglipron does the same job as semaglutide — activating the GLP-1 receptor to curb appetite and improve blood sugar — but it's a small molecule you can swallow, not an injectable peptide. That's a big deal for convenience and manufacturing: a daily GLP-1 pill could reach far more people than injections. In large phase 3 trials it delivered solid results (~11% weight loss, meaningful HbA1c drops). The trade-off is that its weight-loss effect, while real, tops out below the best injectables, and it comes with the same gastrointestinal side effects as the class.
The GLP-1 appetite dial in pill form — more convenient than the injections, but it doesn't turn as far as the strongest of them.
GLP-1R agonism (non-peptide)
A small-molecule agonist at the GLP-1 receptor — orally bioavailable, unlike peptide GLP-1 drugs that require injection or complex oral formulation.
Weight + glycemic effect
~11% weight loss (obesity) and ~1.5-pp HbA1c reduction (early T2D) in phase 3.
Efficacy tier
Below injectable semaglutide/tirzepatide on weight loss, but far more convenient.
Evidence stage
Positive phase 3 program (ATTAIN/ACHIEVE); late-stage, not yet approved.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Orforglipron has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Titration
→ 6 / 12 / 36 mg
Once-daily oral, escalated to limit GI effects (trial doses).
·
Doses below are from clinical trials, not instructions. Orforglipron is not yet approved.
·
Once-daily oral dosing is the key practical feature.
·
GI side effects are worst during dose escalation.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Nausea
Class GLP-1 effect; worst during escalation.
Common
Diarrhea / constipation
GI-dominant profile.
Common
Vomiting
Dose-related.
Common
Serious · rare
GI-related discontinuation
Higher than placebo; the main tolerability limit.
~5–10%
Class cautions
GLP-1 class cautions (pancreatitis, gallbladder) apply pending full data.
Under study
Absolute · do not use
×
Pregnancy, planned pregnancy, or breastfeeding (not studied; weight loss generally not advised in pregnancy)
×
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (per GLP-1 receptor agonist class labeling)
×
History of pancreatitis (use with caution; class-level concern)
×
Known serious hypersensitivity to orforglipron or any excipient in the product
×
Active or severe gastrointestinal disease in which slowed gastric emptying could worsen symptoms
×
Always defer to the complete contraindications and warnings in the FDA-approved Foundayo prescribing information
Relative · discuss first
!
History of pancreatitis — GLP-1 class caution
!
Severe GI disease / gastroparesis — delayed emptying
!
Pregnancy or breastfeeding — insufficient data
!
Those prioritizing maximal weight loss — injectables reach further
Interactions
Insulin
Increased risk of hypoglycemia when combined with a GLP-1 receptor agonist; the insulin dose may need to be reduced under medical supervision
Major
Sulfonylureas (e.g., glipizide, glimepiride)
Increased risk of hypoglycemia in combination; dose reduction of the sulfonylurea may be warranted
Major
Oral medications with narrow therapeutic index
GLP-1 receptor agonists slow gastric emptying, which can theoretically alter the rate or extent of absorption of co-administered oral drugs
Moderate
Oral contraceptives
Theoretical reduction in absorption due to delayed gastric emptying; not specifically characterized for orforglipron, so additional contraceptive caution may be prudent
Moderate
Other GLP-1 receptor agonists or incretin-based therapies
Overlapping mechanism with no added benefit and additive gastrointestinal and hypoglycemia risk; concurrent use is not appropriate
Major
Labs to monitor
Body weight / BMI
Baseline and periodically during treatment
Primary efficacy measure for the weight-management indication; tracks response and informs continuation decisions
HbA1c
Baseline and every 3 months if diabetic
Relevant when used in people with type 2 diabetes; reflects longer-term glycemic response seen in the ACHIEVE and ATTAIN-2 trials
Fasting glucose
Baseline and as clinically indicated
Helps detect hypoglycemia risk, especially if combined with insulin or a sulfonylurea
Lipid panel
Baseline and periodically
Trials showed reductions in triglycerides and non-HDL/LDL cholesterol; useful for tracking cardiometabolic response
Blood pressure
Baseline and at follow-up visits
Systolic blood pressure improved with orforglipron in the phase 3 trials; relevant to overall cardiometabolic monitoring
Part 04 · Evidence
How strong is the evidence?
82
Grade A
Grade A. A large, positive phase 3 program for an oral GLP-1 — a potentially transformative convenience advance. The ceiling on the score: weight loss is below the best injectables, GI discontinuation is non-trivial, and it is not yet approved.
Mechanistic plausibility
Well-validated GLP-1 biology delivered orally as a small molecule.
88
Human evidence
Multiple large phase 3 trials (obesity + diabetes) with consistent results.
86
Efficacy vs class
~11% weight loss — real, but below injectable semaglutide/tirzepatide.
70
Safety & tolerability
Class-typical GI effects; discontinuation up to ~10%.
74
Independence
Lilly-sponsored phase 3; large, prespecified, multinational.
72
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2025
New England Journal of Medicine Industry funded
ATTAIN-1 — oral orforglipron in obesity (phase 3)
36 mg produced −11.2% weight loss vs −2.1% placebo; 36% achieved ≥15% loss. GI adverse events most common; discontinuation 5–10%.
Phase 3 RCT, 72 wk, placebo-controlled · n = 3,127 · Lilly-sponsored; large and prespecified.
PMID 40960239 ↗
High
02
2025
New England Journal of Medicine Industry funded
ACHIEVE-1 — orforglipron in early type 2 diabetes (phase 3)
HbA1c fell ~1.48 pp (36 mg) with weight loss −7.6%; no severe hypoglycemia.
Phase 3 RCT, 40 wk, placebo-controlled · n = 559 · Lilly-sponsored; consistent with the class.
PMID 40544435 ↗
High
03
2023
New England Journal of Medicine Industry funded
Phase 2 oral orforglipron in obesity
Up to −14.7% weight loss at 36 weeks vs −2.3% placebo — the signal that launched the phase 3 program.
Phase 2 RCT, 36 wk · n = 272 · Dose-finding; higher phase-2 numbers than phase 3, as often occurs.
PMID 37351564 ↗
High
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Lower weight-loss ceiling than injectable leaders
Lost head-to-head NEJM (ATTAIN-1) · 2025
Orforglipron's ~11% weight loss, while strong for a pill, is below injectable semaglutide (~15%) and well below tirzepatide (~20%).
What this means: Its edge is convenience, not maximal efficacy. Someone prioritizing the greatest weight loss would still choose an injectable.
PMID 40960239 ↗
02
Class-typical GI effects and meaningful discontinuation
Safety signal NEJM (ATTAIN-1) · 2025
Gastrointestinal effects led to treatment discontinuation in roughly 5–10% of orforglipron patients — the familiar GLP-1 tolerability tax.
What this means: Oral does not mean gentler; the GI profile mirrors the injectables and drives some dropout.
PMID 40960239 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Investigational (filing-stage)
Not yet approved; phase 3 complete and under regulatory submission. No consumer product yet.
N/A pending approval
European Union
Investigational
Not yet approved.
N/A
United Kingdom
Investigational
Not yet approved.
N/A
Canada
Investigational
Not yet approved.
N/A
The Peptide Column takes no affiliate commission from any source. Orforglipron is an investigational oral GLP-1 (a small molecule, not a peptide) with positive phase 3 data but no approval yet; any product sold as 'orforglipron' now is unregulated. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Given my weight, blood sugar, and other medications, is an oral GLP-1 like orforglipron a reasonable option for me versus an injectable GLP-1?
02
What gradual dose-escalation schedule will you use to limit nausea and other gastrointestinal side effects?
03
If I take medications such as insulin or a sulfonylurea, do those doses need to be lowered to avoid low blood sugar?
04
What is the plan if I cannot tolerate the side effects or do not lose a meaningful amount of weight after several months?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. ATTAIN-1 — oral orforglipron in obesity (phase 3) · New England Journal of Medicine, 2025 · PMID 40960239 ↗
- 02. ACHIEVE-1 — orforglipron in early type 2 diabetes (phase 3) · New England Journal of Medicine, 2025 · PMID 40544435 ↗
- 03.
- 04.